Synonyms: ASP-1941 | ASP1941 | Suglat®
ipragliflozin is an approved drug (Japan (2014))
Compound class:
Synthetic organic
Comment: Ipragliflozin is a selective and orally available sodium/glucose cotransporter 2 (SGLT2; SLC5A2) inhibitor [2,4] (a 'gliflozin' family drug [1]) used to treat type 2 diabetes. In practice ipragliflozin is complexed with L-proline in a 1:1 ratio.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Ipragliflozin is approved for use in Japan, the Republic of Korea and Thailand, for the treatment of type 2 diabetes. Phase 3 clinical trial results are reported in [3]. |